AGRX stock forecast
Our latest prediction for Agile Therapeutics Inc's stock price was made on the July 29, 2021 when the stock price was at 1.21$.
In the short term (2weeks), AGRX's stock price should outperform the market by 2.48%. During that period the price should oscillate between -10.36% and +18.17%.
In the medium term (3months), AGRX's stock price should outperform the market by 18.15%. During that period the price should oscillate between -44.50% and +55.06%.Get email alerts
Create a solid portfolio with AGRX
About Agile Therapeutics Inc
Agile Therapeutics is a forward-looking women's healthcare company dedicated to fulfilling the unmet health needs of today's women. Its product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. The Company's initial product, Twirla®, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on Company's proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin. The Company may occasionally disseminate material, nonpublic information on the Company's website.
At the moment the company generates 2M USD in revenues.
On its last earning announcement, the company reported a loss of -0.77$ per share.
The book value per share is 0.76$
Three months stock forecastJuly 29, 2021
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|